We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$15.6B
AUM Growth
+$1.15B
Cap. Flow
-$252M
Cap. Flow %
-1.61%
Top 10 Hldgs %
27.58%
Holding
750
New
44
Increased
354
Reduced
220
Closed
56

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$64.3M
2
AAPL icon
Apple
AAPL
+$53M
3
CRM icon
Salesforce
CRM
+$52.8M
4
AMAT icon
Applied Materials
AMAT
+$42.9M
5
MU icon
Micron Technology
MU
+$41.3M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$68.6M
2
ADBE icon
Adobe
ADBE
+$58.8M
3
ANSS
Ansys
ANSS
+$52.1M
4
TJX icon
TJX Companies
TJX
+$39.6M
5
TMO icon
Thermo Fisher Scientific
TMO
+$38.3M

Sector Composition

Rank Sector Weight
1 Technology 31.73%
2 Healthcare 28.37%
3 Financials 8.73%
4 Consumer Discretionary 8.29%
5 Industrials 6.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
INTU icon
101
Intuit
INTU
$85.6B
$36.2M 0.23%
55,647
+11,165
+25% +$7.13M
BKNG icon
102
Booking.com
BKNG
$154B
$36.1M 0.23%
249,025
+186,650
+299% +$26.6M
XYL icon
103
Xylem
XYL
$29.2B
$35.6M 0.23%
275,163
+11,414
+4% +$1.38M
KLAC icon
104
KLA
KLAC
$249B
$35.3M 0.23%
505,360
-26,270
-5% -$1.69M
FTV icon
105
Fortive
FTV
$19.5B
$35.1M 0.22%
542,183
-90,551
-14% -$5.5M
AMP icon
106
Ameriprise Financial
AMP
$48.3B
$35M 0.22%
79,938
+18,573
+30% +$7.44M
FSLR icon
107
First Solar
FSLR
$21.8B
$34.8M 0.22%
206,209
-6,211
-3% -$955K
CYTK icon
108
Cytokinetics
CYTK
$10.8B
$34.6M 0.22%
493,029
+225,789
+84% +$17.5M
ABT icon
109
Abbott
ABT
$187B
$34.5M 0.22%
303,509
-322,925
-52% -$37M
APLS
110
DELISTED
Apellis Pharmaceuticals
APLS
$34.4M 0.22%
584,925
+247,418
+73% +$15.8M
OLED icon
111
Universal Display
OLED
$3.85B
$33.6M 0.21%
199,228
LULU icon
112
lululemon athletica
LULU
$13.7B
$33.2M 0.21%
84,933
+5,975
+8% +$2.76M
BMRN icon
113
BioMarin Pharmaceuticals
BMRN
$12B
$33M 0.21%
378,311
+91,383
+32% +$8.18M
HCA icon
114
HCA Healthcare
HCA
$92.8B
$33M 0.21%
98,833
+233
+0.2% +$71.2K
DDOG icon
115
Datadog
DDOG
$89.3B
$31.8M 0.2%
257,117
+2,526
+1% +$318K
OC icon
116
Owens Corning
OC
$11.5B
$31.5M 0.2%
188,733
+48,467
+35% +$7.39M
CNC icon
117
Centene
CNC
$31.6B
$31.3M 0.2%
399,224
+52,795
+15% +$4.08M
KO icon
118
Coca-Cola
KO
$380B
$30.1M 0.19%
492,208
-28,584
-5% -$1.72M
NU icon
119
Nu Holdings
NU
$70.9B
$29.9M 0.19%
2,502,238
-2,194,200
-47% -$22.4M
A icon
120
Agilent Technologies
A
$39.7B
$29.8M 0.19%
205,005
-12,402
-6% -$1.7M
XOM icon
121
ExxonMobil
XOM
$634B
$29.8M 0.19%
256,451
+21,991
+9% +$2.3M
FISV
122
Fiserv Inc
FISV
$28.9B
$29.6M 0.19%
185,434
-4,526
-2% -$659K
BSX icon
123
Boston Scientific
BSX
$68.5B
$29M 0.19%
423,011
-64,488
-13% -$4.15M
OTIS icon
124
Otis Worldwide
OTIS
$28B
$28.8M 0.18%
289,772
+4,762
+2% +$440K
PDD icon
125
Pinduoduo
PDD
$122B
$28.4M 0.18%
244,400
-67,660
-22% -$8.86M

Similar funds

Candriam SCA's Q1 2024 Portfolio in Review

As of Q1 2024, Candriam SCA held 750 positions worth $15.6B, up 7.9% from $14.5B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Candriam SCA's Q1 2024 filing shows 44 new, 354 increased, 220 reduced and 56 closed positions. Its largest new stake was Altair Engineering Inc: 434,749 shares worth $37.5M. The largest sale was Merck, an estimated $68.6M.

By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q1 2024 buy was Altair Engineering Inc: 434,749 shares worth $37.5M.
  • Candriam SCA added most to NVIDIA in Q1 2024, an estimated $64.3M increase.
  • Candriam SCA's biggest Q1 2024 reduction was Merck, cutting an estimated $68.6M.
  • Candriam SCA fully exited Immunogen Inc in Q1 2024, selling an estimated $33.3M.
  • Candriam SCA's ten largest holdings make up 28% of its $15.6B portfolio in Q1 2024.
  • Candriam SCA opened 44 new positions and closed 56 in Q1 2024.
  • Candriam SCA's portfolio value rose 7.9% quarter-over-quarter to $15.6B.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.